ARDX — ARDELYX, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1437402 ·
Last close
$3.18
Market Cap
$799.36M
52W High
$8.40
52W Low
$2.80
ADV30
4,760,461
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 127,655,000 | 123,116,000 | 4,023,000 | -737,000 | 587,525,000 | 46,317,000 | 423,479,000 |
| Jun 2026 | 120,877,000 | 115,118,000 | -12,425,000 | -16,721,000 | 575,894,000 | 97,191,000 | 426,881,000 |
| Mar 2026 | 94,473,000 | 89,662,000 | -32,793,000 | -37,605,000 | 504,507,000 | 31,209,000 | 355,885,000 |
| Dec 2025 | 125,215,000 | 114,366,000 | 5,099,000 | -407,000 | 501,604,000 | 67,999,000 | 334,655,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,514,000
Investing CF
$-37,562,000
Financing CF
$56,678,000
CapEx
$-599,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.22
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,002,002,000
Inventory
$24,440,000
Receivables
$93,441,000
ST Investments
$239,021,000
EBIT TTM
$-27,156,000
Pretax Income TTM
$-55,255,000
Interest Exp TTM
$28,099,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$468,220,000
EBITDA
$-33,035,000
Free Cash Flow
$33,018,124
Enterprise Value
$722,168,960
Total Cash
$285,337,984
Total Debt
$283,553,984
Shares Out
251,372,553
Trailing EPS
$-0.23
Book Value
$0.65
ROE
-34.9%
ROA
-4.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 407,320,000 | -40,977,000 | -61,599,000 | 501,604,000 | 334,655,000 | 166,949,000 | -42,483,000 |
| Dec 2024 | 333,615,000 | -27,950,000 | -39,136,000 | 435,754,000 | 262,465,000 | 173,289,000 | -44,809,000 |
| Dec 2023 | 124,456,000 | -63,276,000 | -66,067,000 | 297,579,000 | 130,763,000 | 166,816,000 | -89,717,000 |
| Dec 2022 | 52,158,000 | -63,759,000 | -67,207,000 | 190,066,000 | 91,737,000 | 98,329,000 | -70,044,000 |
TTM Snapshot
Revenues TTM
$450,894,000
NetIncome TTM
$-55,702,000
OpCashFlow TTM
—
Assets (Latest)
$575,894,000
Forward EPS
$0.24
Max Pain — expiry 2027-01-15
max pain strike: $4.00 · spot: $3.12 · call oi: 19,884 · put oi: 186,937
Expected Move to 2027-01-15:
±$0.48
(15.22%) —
implied range
$2.64 –
$3.59
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $793.98M | $25.55 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $806.23M | $4.87 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $792.52M | $1.78 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $808.18M | $42.92 | — |
| SNDX | Syndax Pharmaceuticals Inc | $828.26M | $9.20 | — |
News headlines (Yahoo Finance, 1h cache)
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
2026-11-10 12:30 · Yahoo
Ardelyx (ARDX) Stock Looks Cheap Relative To Its Sales Base
2026-11-04 22:16 · Yahoo
Ardelyx (ARDX) Results And IBSRELA Progress Put Its Valuation Story Back In Focus
2026-11-04 21:11 · Yahoo
Ardelyx: 3 Key Takeaways for Long-Term Investors
2026-11-04 15:27 · Yahoo
Ardelyx (ARDX) Q3 2026 Earnings Call Transcript
2026-11-04 15:00 · Yahoo
Ardelyx, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines and ...
2026-11-04 05:12 · Yahoo
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
2026-11-04 00:14 · Yahoo
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
2026-11-03 21:30 · Yahoo
Ardelyx: Q3 Earnings Snapshot
2026-11-03 21:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.